Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | I01CX001734-01A1 |
| Title: | Pharmacogenetic Study of Opioid Agonist Treatments in MVP |
| Principal Investigator: | Kyle M. Kampman |
| Location: | Philadelphia, PA |
| Congressional District Code: | 3 |
| Research Service: | Clinical Science R&D |
| Project Period: | April 2019 - March 2022 |
| FY 2021 Funding Amount: | $139,767 |
| Total Award Amount (all years): |
$378,175 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: 1. Objectives: In the US, opioids are widely used for maintenance treatment of opioid use disorder (OUD) and to manage acute and chronic pain. Over the past three decades, efforts to treat pain aggressively in the absence of objective markers to guide opioid prescribing have led to a quadrupling of opioid prescriptions, an epidemic of opioid misuse and abuse, and a tripling of the overdose death rate in the general population and among Veterans. The overarching objective of this proposal is... |